AE37
|
|
|
- CAS号:
- 195615-83-9
- 英文名:
- AVex-73
- 英文别名:
- AE38;AE37;CS-2603;AVex-73;ANAVEX-2-73(Blarcamesine);Blarcamesine (Anavex-2-73);1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;3-Furanmethanamine, tetrahydro-N,N-dimethyl-2,2-diphenyl-;syndrome,Inhibitor,Muscarinic acetylcholine receptor,inhibit,mAChR,Rett,anticonvulsant,Blarcamesine,anti-amnesic,antidepressant,Sigma Receptor,Alzheimer's,disease,neuroprotective
- 中文名:
- AE37
- 中文别名:
- 化合物AVEX-73
- CBNumber:
- CB73152183
- 分子式:
- C19H23NO
- 分子量:
- 281.39
- MOL File:
- 195615-83-9.mol
|
|
|
AE37性质、用途与生产工艺
Blarcamesine (AVex-73;AE-37) 是一种 Sigma-1 受体激动剂和毒蕈碱受体 (muscarinic receptor) 调节剂，具有抗惊厥、抗失忆、神经保护和抗抑郁的特性。Blarcamesine 能改善 Rett 综合征小鼠模型的神经功能损害。
Sigma-1 receptor, muscarinic receptor
Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration.
Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice.
Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response.
Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice.
|
Animal Model:
|
Female Mecp2
tm1.1Bird
/J HET (C57 background) mice
|
|
Dosage:
|
10 mg/kg, 30 mg/kg
|
|
Administration:
|
Oral administration, daily, for 6.5 weeks
|
|
Result:
|
Reverse the deficits observed in the HET animals.
|
AE37
上下游产品信息
上游原料
下游产品
195615-83-9, AE37 相关搜索:
- APIS
- 化合物AVEX-73
- 195615-83-9
- syndrome,Inhibitor,Muscarinic acetylcholine receptor,inhibit,mAChR,Rett,anticonvulsant,Blarcamesine,anti-amnesic,antidepressant,Sigma Receptor,Alzheimer's,disease,neuroprotective
- AE38
- AE37
- 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
- CS-2603
- 3-Furanmethanamine, tetrahydro-N,N-dimethyl-2,2-diphenyl-
- Blarcamesine (Anavex-2-73)
- ANAVEX-2-73(Blarcamesine)
- AVex-73